Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
Abstract Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in prospectively collected tumour samples from 25 CRC...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2019-10-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-019-51981-5 |
id |
doaj-f456fa8deb9947ea89d5b6e8de43eb83 |
---|---|
record_format |
Article |
spelling |
doaj-f456fa8deb9947ea89d5b6e8de43eb832020-12-08T07:30:35ZengNature Publishing GroupScientific Reports2045-23222019-10-019111310.1038/s41598-019-51981-5Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patientsSteven M. Bray0Jeeyun Lee1Seung Tae Kim2Joon Young Hur3Philip J. Ebert4John N. Calley5Isabella H. Wulur6Thejaswini Gopalappa7Swee Seong Wong8Hui-Rong Qian9Jason C. Ting10Jiangang Liu11Melinda D. Willard12Ruslan D. Novosiadly13Young Suk Park14Joon Oh Park15Ho Yeong Lim16Won Ki Kang17Amit Aggarwal18Hee Cheol Kim19Christoph Reinhard20Eli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchDivision of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of MedicineDivision of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of MedicineDivision of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of MedicineEli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchEli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchEli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchEli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchEli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchEli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchEli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchEli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchEli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchEli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchDivision of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of MedicineDivision of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of MedicineDivision of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of MedicineDivision of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of MedicineEli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchDepartment of Surgery, Samsung Medical Center, Sungkyunkwan University School of MedicineEli Lilly and Company, Lilly Research Laboratories, Oncology Discovery ResearchAbstract Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in prospectively collected tumour samples from 25 CRC patients receiving cetuximab (an EGFR inhibitor). Of 25 CRC patients, 13 displayed intrinsic resistance to cetuximab; 12 were intrinsically sensitive. We obtained six re-biopsy samples at acquired resistance from the intrinsically sensitive patients. NCOA4–RET and LMNA–NTRK1 fusions and NRG1 and GNAS amplifications were found in intrinsic-resistant patients. In cetuximab-sensitive patients, we found KRAS K117N and A146T mutations in addition to BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications. The comparison between baseline and acquired-resistant tumours revealed an extreme shift in variant allele frequency of somatic variants, suggesting that cetuximab exposure dramatically selected for rare resistant subclones that were initially undetectable. There was also an increase in epithelial-to-mesenchymal transition at acquired resistance, with a reduction in the immune infiltrate. Furthermore, characterization of an acquired-resistant, patient-derived cell line showed that PI3K/mTOR inhibition could rescue cetuximab resistance. Thus, we uncovered novel genomic alterations that elucidate the mechanisms of sensitivity and resistance to anti-EGFR therapy in metastatic CRC patients.https://doi.org/10.1038/s41598-019-51981-5 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Steven M. Bray Jeeyun Lee Seung Tae Kim Joon Young Hur Philip J. Ebert John N. Calley Isabella H. Wulur Thejaswini Gopalappa Swee Seong Wong Hui-Rong Qian Jason C. Ting Jiangang Liu Melinda D. Willard Ruslan D. Novosiadly Young Suk Park Joon Oh Park Ho Yeong Lim Won Ki Kang Amit Aggarwal Hee Cheol Kim Christoph Reinhard |
spellingShingle |
Steven M. Bray Jeeyun Lee Seung Tae Kim Joon Young Hur Philip J. Ebert John N. Calley Isabella H. Wulur Thejaswini Gopalappa Swee Seong Wong Hui-Rong Qian Jason C. Ting Jiangang Liu Melinda D. Willard Ruslan D. Novosiadly Young Suk Park Joon Oh Park Ho Yeong Lim Won Ki Kang Amit Aggarwal Hee Cheol Kim Christoph Reinhard Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients Scientific Reports |
author_facet |
Steven M. Bray Jeeyun Lee Seung Tae Kim Joon Young Hur Philip J. Ebert John N. Calley Isabella H. Wulur Thejaswini Gopalappa Swee Seong Wong Hui-Rong Qian Jason C. Ting Jiangang Liu Melinda D. Willard Ruslan D. Novosiadly Young Suk Park Joon Oh Park Ho Yeong Lim Won Ki Kang Amit Aggarwal Hee Cheol Kim Christoph Reinhard |
author_sort |
Steven M. Bray |
title |
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients |
title_short |
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients |
title_full |
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients |
title_fullStr |
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients |
title_full_unstemmed |
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients |
title_sort |
genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2019-10-01 |
description |
Abstract Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in prospectively collected tumour samples from 25 CRC patients receiving cetuximab (an EGFR inhibitor). Of 25 CRC patients, 13 displayed intrinsic resistance to cetuximab; 12 were intrinsically sensitive. We obtained six re-biopsy samples at acquired resistance from the intrinsically sensitive patients. NCOA4–RET and LMNA–NTRK1 fusions and NRG1 and GNAS amplifications were found in intrinsic-resistant patients. In cetuximab-sensitive patients, we found KRAS K117N and A146T mutations in addition to BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications. The comparison between baseline and acquired-resistant tumours revealed an extreme shift in variant allele frequency of somatic variants, suggesting that cetuximab exposure dramatically selected for rare resistant subclones that were initially undetectable. There was also an increase in epithelial-to-mesenchymal transition at acquired resistance, with a reduction in the immune infiltrate. Furthermore, characterization of an acquired-resistant, patient-derived cell line showed that PI3K/mTOR inhibition could rescue cetuximab resistance. Thus, we uncovered novel genomic alterations that elucidate the mechanisms of sensitivity and resistance to anti-EGFR therapy in metastatic CRC patients. |
url |
https://doi.org/10.1038/s41598-019-51981-5 |
work_keys_str_mv |
AT stevenmbray genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT jeeyunlee genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT seungtaekim genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT joonyounghur genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT philipjebert genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT johnncalley genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT isabellahwulur genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT thejaswinigopalappa genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT sweeseongwong genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT huirongqian genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT jasoncting genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT jiangangliu genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT melindadwillard genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT ruslandnovosiadly genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT youngsukpark genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT joonohpark genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT hoyeonglim genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT wonkikang genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT amitaggarwal genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT heecheolkim genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients AT christophreinhard genomiccharacterizationofintrinsicandacquiredresistancetocetuximabincolorectalcancerpatients |
_version_ |
1724391235126296576 |